Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Drs Tsujimoto and Yamamoto-Honda note that improvements in adherence are of benefit in terms of increasing uptake of proven antiplatelet therapy, but question the importance of the improvements in mean LDL-C level and SBP. In contrast to their suggestion, in high-risk cardiovascular patients there is clear evidence of benefits of blood pressure lowering in patients without hypertension and of more vs less blood pressure lowering1- 3; similarly, there are benefits of LDL-C level lowering in patients without hyperlipidemia and of more vs less LDL-C level lowering.4,5
Thom S, Rodgers A. Combination Pill for Cardiovascular Disease—Reply. JAMA. 2014;311(1):93-94. doi:10.1001/jama.2013.283146